Laurus Labs Ltd. (LAURUSLABS) fundamentals
Laurus Labs Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as LAURUSLABS (ISIN INE947Q01028). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Laurus Labs Ltd. does
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers an integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, CDMO custom synthesis (Laurus Synthesis), and Biotechnology (Laurus Bio). The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. Its solutions cater for sectors, such as regenerative medicine, vaccines, cultured meat, and others.
Valuation and market data
| Last close | ₹1969.00 |
|---|---|
| Market capitalisation | ₹1.06 lakh crore |
| Enterprise value | ₹1.08 lakh crore |
| P/E (TTM) | 119.55 |
| Price to book | 19.59 |
| Price to sales (TTM) | 8.64 |
| Book value per share | ₹100.53 |
| Dividend yield | 10.16% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Dec 19 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹6,868 crore | ₹1,182 crore | ₹890 crore | 16.47 |
| Mar 2025 | ₹5,629 crore | ₹484 crore | ₹354 crore | 6.65 |
| Mar 2024 | ₹5,067 crore | ₹236 crore | ₹168 crore | 2.98 |
| Mar 2023 | ₹6,047 crore | ₹1,109 crore | ₹797 crore | 14.69 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 27.5% |
|---|---|
| Foreign institutions (FII) | 28.0% |
| Mutual funds | 10.2% |
| Other domestic institutions | 3.6% |
| Retail and others | 30.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.